Myriad Genetics (NASDAQ:MYGN) slumps 26% premarket on light volume in reaction to its fiscal Q4 results that were shy of consensus. Highlights:
Revenue: $215.4M (+11%); Molecular Diagnostic Testing: $196.9M (+9%); Hereditary Cancer: $119.0M (flat); GeneSight: $29.8M (-12%). Revenue pressured by lower reimbursement for its expanded carrier screening test.
Net loss: ($4.2M) (-129%); loss/share: ($0.06) (-130%); non-GAAP EPS: $0.41 (-5%).
Cash flow ops (full year): $83.7M (-28%).
Fiscal Q1 guidance: Revenue: $200M – 202M; EPS: ($0.02) – 0.00; non-GAAP EPS: $0.30 – 0.32.
Fiscal 2020 guidance: Revenue: $865M – 875M; EPS: $0.55 – 0.65; non-GAAP EPS: $1.80 – 1.90.
Previously: Myriad Genetics EPS misses by $0.07, misses on revenue (Aug. 13)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.